No significant differences in terms of demographics (age, sex, burden of comorbidities, and most prevalent comorbidity), AML type, ELN2022 risk, the presence of NPM1 or FLT3 mutations, and the duration of neutropenia were observed across the two groups (caspofungin vs. posaconazole prophylaxis). This evidence concerns the gene FLT3 and acute myeloid leukemia.